KORU Medical Systems (NASDAQ:KRMD) Announces Earnings Results

KORU Medical Systems (NASDAQ:KRMD) released its earnings results on Tuesday. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.02) by $0.04, FiscalAI reports. The business had revenue of $11.57 million during the quarter, compared to the consensus estimate of $11.33 million. KORU Medical Systems had a negative return on equity of 4.75% and a negative net margin of 1.78%.

Here are the key takeaways from KORU Medical Systems’ conference call:

• Q3 revenue grew 11% to $11.6 million, though growth slowed as expected amid international timing effects. On a normalized basis, domestic core revenue grew 10% and international core grew 23%; management expects high-teens growth in Q4.
• Profitability and margins improved: gross margin rose 500 basis points year over year to 65.2%, and the company reported its second consecutive quarter of positive net income, alongside progress in adjusted EBITDA.
• KORU raised its 2026 outlook: revenue guidance is now $48 million–$48.5 million, gross margin guidance is 63%–64%, and the company expects positive full-year adjusted EBITDA and year-end cash above $8 million.
• Commercial and product initiatives broaden potential growth: new distribution agreements in Europe and Africa, three specialty pharmacies dispensing KORU products for RYSTIGGO home administration, and progress on drug programs and the Freedom360 pump could expand reach, though several opportunities remain subject to partner timelines and regulatory review.

KORU Medical Systems Stock Performance

KRMD stock traded up $0.13 during midday trading on Thursday, reaching $4.02. 88,108 shares of the company’s stock traded hands, compared to its average volume of 186,782. The company has a 50-day moving average price of $3.13 and a two-hundred day moving average price of $3.94. KORU Medical Systems has a 52 week low of $2.86 and a 52 week high of $6.61. The firm has a market capitalization of $184.64 million, a PE ratio of -201.00 and a beta of 0.47.

Insider Activity

In related news, insider Adam Kalbermatten purchased 32,000 shares of the business’s stock in a transaction dated Tuesday, September 8th. The stock was purchased at an average cost of $3.16 per share, with a total value of $101,120.00. Following the completion of the acquisition, the insider directly owned 394,017 shares of the company’s stock, valued at approximately $1,245,093.72. The trade was a 8.84% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 18.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings downgraded KORU Medical Systems from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, September 29th. Zacks Research cut KORU Medical Systems from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 30th. Craig Hallum restated a “buy” rating and issued a $6.00 price objective on shares of KORU Medical Systems in a research note on Thursday, August 6th. Piper Sandler reaffirmed a “neutral” rating and set a $4.50 price objective (down from $5.00) on shares of KORU Medical Systems in a report on Wednesday. Finally, Wall Street Zen lowered shares of KORU Medical Systems from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $6.50.

About KORU Medical Systems

KORU Medical Systems, Inc. develops, manufactures and markets portable infusion systems and related accessories for the home and alternate-site infusion markets. The company’s products are designed to support the controlled delivery of specialty drugs, including subcutaneous immunoglobulin (SCIG) therapies, through ambulatory infusion systems. KORU’s principal product platform is the Freedom Syringe Infusion System, which includes ambulatory syringe pumps such as the Freedom60, FreedomEdge and FreedomIQ, along with flow-control tubing sets and other disposable components.